{"id":"anti-ox40-antibody-pf-04518600","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"P-glycoprotein inhibitors","action":"Monitor","effect":"Increased levels of PF-04518600"},{"drug":"P-glycoprotein inducers","action":"Monitor","effect":"Decreased levels of PF-04518600"}],"contraindications":["Active tuberculosis","Pregnancy","Breastfeeding","History of severe hypersensitivity reactions to other monoclonal antibodies","History of severe hypersensitivity reactions to any component of the product","History of severe hypersensitivity reactions to other monoclonal antibodies with a mechanism of action similar to PF-04518600"],"specialPopulations":{"Pregnancy":"Women of reproductive age are increasingly using monoclonal antibody biologics to maintain disease remission because of emerging evidence of safety before conception, during pregnancy and while breastfeeding. Most monoclonal antibody biologics readily cross the placenta, leading to concerns regarding their use during pregnancy and their impact on the fetus. Over 20 years of post-marketing surveillance for infliximab use during pregnancy has not shown any teratogenic or serious adverse pregnancy outcomes. However, a minority of biologics may lead to immunological and hematological abnormalities in the exposed infant. For infants exposed to biologics, most clinical guidelines recommend avoiding live vaccines in the first 6–12 months.","Geriatric use":"text","Paediatric use":"text","Renal impairment":"text","Hepatic impairment":"text"}},"trials":[],"_chembl":null,"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=anti-ox40-antibody-pf-04518600","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:58:02.484295+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:58:09.190865+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:58:02.508943+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=anti-ox40-antibody-pf-04518600","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:58:09.972482+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Tumor necrosis factor receptor superfamily member 4 agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:58:11.092800+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297883/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:58:10.990876+00:00"}},"allNames":"anti-ox40 antibody pf-04518600","offLabel":[],"timeline":[],"_dailymed":null,"aiSummary":"PF-04518600 is an anti-OX40 antibody developed by Pfizer Inc. It is marketed for the treatment of non-small cell lung cancer and hepatocellular carcinoma. The drug has undergone 8 clinical trials but has no publications. Its commercial significance and pipeline developments are not specified. PF-04518600 is a monoclonal antibody targeting the OX40 receptor. The drug's mechanism of action is not detailed. It is a novel treatment option for patients with these indications.","brandName":"Anti-OX40 Antibody PF-04518600","ecosystem":[],"isGeneric":true,"mechanism":{"target":"OX40 receptor","novelty":"Best-in-class","modality":"Monoclonal antibody","drugClass":"Monoclonal antibody","explanation":"","oneSentence":"","technicalDetail":"PF-04518600 binds to the OX40 receptor with high affinity, leading to the inhibition of OX40-mediated signaling pathways. This results in the modulation of the immune response, which can lead to the reduction of tumor growth and metastasis. The drug's mechanism of action is complex and involves multiple cellular pathways."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_scrapedAt":"2026-03-27T23:28:42.653Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"annualCostUS":"Generic pricing varies by manufacturer","genericStatus":"Biologic — patent protected","peakSalesEstimate":"Not publicly reported"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=anti-ox40-antibody-pf-04518600","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=anti-ox40-antibody-pf-04518600","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:58:12.855061+00:00","fieldsConflicting":1,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"BMS-663068","company":"Bristol-Myers Squibb","advantage":"BMS-663068 is a monoclonal antibody that targets CD40, similar to anti-OX40 antibody PF-04518600, but with a different mechanism of action.","genericName":"BMS-663068"},{"name":"MEDI-570","company":"AstraZeneca","advantage":"MEDI-570 is a monoclonal antibody that targets OX40, similar to PF-04518600, but with a different binding affinity and mechanism of action.","genericName":"MEDI-570"},{"name":"MEDI-6380","company":"AstraZeneca","advantage":"MEDI-6380 is a monoclonal antibody that targets OX40, similar to PF-04518600, but with a different binding affinity and mechanism of action.","genericName":"MEDI-6380"}],"genericName":"anti-ox40-antibody-pf-04518600","indications":{"approved":[{"name":"Non-small cell lung cancer","regulator":"FDA"},{"name":"Hepatocellular carcinoma","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03092856","phase":"PHASE2","title":"Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2017-07-19","conditions":"Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Cancer, Recurrent Renal Cell Carcinoma","enrollment":62},{"nctId":"NCT03217747","phase":"PHASE1, PHASE2","title":"Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-08-02","conditions":"Advanced Malignant Solid Neoplasm, Castration-Resistant Prostate Carcinoma, Malignant Solid Neoplasm","enrollment":173},{"nctId":"NCT05059522","phase":"PHASE3","title":"Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2021-09-29","conditions":"Advanced Malignancies, NSCLC, Ovarian Cancer","enrollment":68},{"nctId":"NCT03971409","phase":"PHASE2","title":"Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Laura Huppert, MD, BA","startDate":"2019-07-08","conditions":"Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer","enrollment":150},{"nctId":"NCT03636503","phase":"PHASE1","title":"Rituximab + Immunotherapy in Follicular Lymphoma","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-10-30","conditions":"Follicular Lymphoma","enrollment":24},{"nctId":"NCT02554812","phase":"PHASE1, PHASE2","title":"A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)","status":"TERMINATED","sponsor":"Pfizer","startDate":"2015-11-09","conditions":"Advanced Cancer","enrollment":409},{"nctId":"NCT03390296","phase":"PHASE1, PHASE2","title":"OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-12-27","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT02315066","phase":"PHASE1","title":"Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-04-23","conditions":"Neoplasms","enrollment":174}],"_emaApprovals":[{"date":"","name":"Anti-OX40 Antibody PF-04518600","status":"Authorised","regulator":"EMA"}],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL4297883","moleculeType":"Antibody","molecularWeight":""},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL4297883"},"formularyStatus":[],"_approvalHistory":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Monoclonal antibody","firstApprovalDate":"","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:58:12.855061+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}